Bianco Fernando J, Scardino Peter T, Stephenson Andrew J, Diblasio Christopher J, Fearn Paul A, Eastham James A
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):448-53. doi: 10.1016/j.ijrobp.2004.09.049.
Salvage radical prostatectomy (RP) may potentially cure patients who have isolated local prostate cancer recurrence after radiotherapy (RT). We report the long-term cancer control associated with salvage RP in a consecutive cohort of patients and identify the variables associated with disease progression and cancer survival.
A total of 100 consecutive patients underwent salvage RP with curative intent for biopsy-confirmed, locally recurrent, prostate cancer after RT. Disease progression after salvage RP was defined as a prostate-specific antigen (PSA) level of > or =0.2 ng/mL or by initiation of androgen deprivation therapy. Cancer-specific mortality was defined as active clinical disease progression despite castration. Cox regression analysis was used to evaluate these endpoints. The median follow-up from RT was 10 years (range, 3-27 years) and from salvage RP was 5 years (range, 1-20 years).
Overall, the 5-year progression-free probability was 55% (95% confidence interval, 46-64%), and the median progression-free interval was 6.4 years. The preoperative PSA level was the only significant pretreatment predictor of disease progression in the multivariate analysis (p = 0.01). The 5-year progression-free probability for patients with a preoperative PSA level of <4, 4-10, and >10 ng/mL was 86%, 55%, and 37%, respectively. The 10-year and 15-year cancer-specific mortality after salvage RP was 27% and 40%, respectively. The median time from disease progression to cancer-specific death was 10.3 years (95% confidence interval, 7.6-12.9). After multivariate analysis, the preoperative serum PSA level and seminal vesicle or lymph node status correlated independently with disease progression.
Greater preoperative PSA levels are associated with disease progression and cancer-specific death. Long-term control of locally recurrent prostate cancer after definitive RT is possible when salvage RP is performed early in the course of recurrent disease.
挽救性根治性前列腺切除术(RP)可能治愈放疗(RT)后孤立性局部前列腺癌复发的患者。我们报告了一组连续患者中挽救性RP的长期癌症控制情况,并确定了与疾病进展和癌症生存相关的变量。
共有100例连续患者接受了挽救性RP,目的是治愈活检证实的放疗后局部复发性前列腺癌。挽救性RP后的疾病进展定义为前列腺特异性抗原(PSA)水平≥0.2 ng/mL或开始雄激素剥夺治疗。癌症特异性死亡率定义为尽管进行了去势仍有活动性临床疾病进展。采用Cox回归分析评估这些终点。从放疗开始的中位随访时间为10年(范围3 - 27年),从挽救性RP开始的中位随访时间为5年(范围1 - 20年)。
总体而言,5年无进展概率为55%(95%置信区间,46 - 64%),中位无进展间隔为6.4年。术前PSA水平是多变量分析中疾病进展的唯一显著术前预测因素(p = 0.01)。术前PSA水平<4、4 - 10和>10 ng/mL的患者5年无进展概率分别为86%、55%和37%。挽救性RP后10年和15年的癌症特异性死亡率分别为27%和40%。从疾病进展到癌症特异性死亡的中位时间为10.3年(95%置信区间,7.6 - 12.9)。多变量分析后,术前血清PSA水平和精囊或淋巴结状态与疾病进展独立相关。
术前PSA水平较高与疾病进展和癌症特异性死亡相关。在复发性疾病过程中早期进行挽救性RP时,有可能对根治性放疗后局部复发性前列腺癌进行长期控制。